Sentences with phrase «pricing of generic drugs»

[3] The sale and pricing of generic drugs is provincially regulated.

Walgreens had forecast that the prices of generic drugs would fall — only to realize that in fact they were rising.

Not exact matches

A 2012 report by the Kaiser Family Foundation calls the PBM assertions of Medicare savings «overstated» and says the reduced cost probably stemmed from incorrectly high predictions of prices and from brand drugs going generic.

However analysts point to a bounce in Teva's shares over the past four months and a slowing in the rate of decline of U.S. generic drug prices as bright spots.

Another bright spot could be the slowing in the decline of U.S. generic drug prices, according to report from Credit Suisse, citing data from health information company IQVIA.

Teva said in a statement it would soon start producing a generic version of the drug that will be «priced significantly lower than Viagra,» which will result in «millions in savings to consumers» and «make this medication accessible to people who might otherwise not have been able to afford it.»

Plus, a handful of companies will typically all get approved to make a generic at once, which ideally creates competition in the marketplace and can sometimes result in even lower prices for those drugs.

Other pain points included drug pricing and how approving more generics may affect costs (Gottlieb parried that question by noting the FDA doesn't have the authority to negotiate prices or consider pricing when approving a drug) and his alleged softness on opioid drug makers due the aforementioned financial ties and pro-industry ideology (the nominee noted that he considers opioid addiction and overdoses a public health crisis «on the order of Ebola and Zika»).

Nothing about the drug has changed in that time, and the fact that it's generic flies in the face of the argument that lack of generic competition is the reason for drastic price hikes.

Lawmakers and regulators (and presidential hopefuls) have been ramping up their scrutiny of drug pricing practices amid several flagrant instances of alleged price gouging (see Turing Pharmaceuticalsand Valeant), and consumer advocates are becoming more vocal about the price of even generic pharmaceuticals.

The companies have begun to market their «biosimilar» (a generic version of expensive biologic drugs) of Remicade — a copycat of J&J's best - selling rheumatoid arthritis and immunology treatment (which garnered more than $ 5 billion in U.S. sales last year) and was approved by the Food and Drug Administration (FDA) in April — at a striking 35 % discount to its list price.

Given its areas of specialization, Gilead wouldn't benefit as much from consolidation as, say, a generic - drug company would, but it still faces pricing pressure: To appease Medicaid and other insurers, Gilead is already steeply discounting its hep - C drugs, which can cost more than $ 80,000 for a 12 - week course.

(Currently, there is a shortage of Valeant's Nitropress, a heart drug that is off - patent but has no generic version — despite the company having tripled the drug's price «overnight» last year, according to the House committee.)

Even after the outrage the drug faced, the price of the branded EpiPen hasn't changed, Duhigg noted on a recent trip to the pharmacy, though the company did introduce a generic that has a list price of $ 300.

The company couldn't say whether its drug price increases have typically occurred before or after a generic version launches, but said that once a generic is available, it would expect to lose so much market share that it «needs to increase the price to keep production of the drug viable.»

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

The whole industry faces turmoil with the advent of laws in several provinces demanding lower prices on generic drugs.

The price of the EpiPen has soared 500 % since generic drug company Mylan (myl) bought the treatment nine years ago.

In Ontario, where the drug reforms began, reimbursements for all generics are down to 25 % of the branded price.

Pharmacies used to be able to charge 50 % or more of the price of a name - brand drug for its generic equivalent.

WASHINGTON (AP)-- Some low - cost generic drugs that have helped restrain health care costs for decades are seeing unexpected price spikes of up to 8,000 percent, prompting a backlash from patients, pharmacists and now Washington lawmakers.

While most of the attention on pharmaceutical prices has been on new drugs for diseases like cancer, hepatitis C and high cholesterol, there is also growing concern about huge price increases on older drugs, some of them generic, that have long been mainstays of treatment.

Teva beats first - quarter expectations but still has the same old problems Copaxone's market share and new generic launches helped Teva to forecast - beating profit and revenue but problems persistTeva had to make pricing concessions on its flagship multiple sclerosis drug Copaxone, and now expects a delay in approval of a key migraine drug, fremanezumab.

This prevented developing countries from producing generic versions of patented drugs, notably treatments for HIV / AIDS and malaria, which they maintained were being sold at unfair prices.

Drug maker Mylan said it will offer a generic version of the life - saving allergy treatment EpiPen for half the list price of the brand - name treatment after it became the center of a national controversy over skyrocketing drug priDrug maker Mylan said it will offer a generic version of the life - saving allergy treatment EpiPen for half the list price of the brand - name treatment after it became the center of a national controversy over skyrocketing drug pridrug prices.

As prescription drug prices — both brand - name and generic — continue to rise, a number of bipartisan proposals to combat the issue have been put on the table.

«A civil war has broken out among the most powerful players in the pharmaceutical industry — including brand - name and generic drug makers, and even your local pharmacists — with each blaming others for the rising price of medicine.»

Decreased market competition causes generic drug prices to rise significantly, according to an article published in Annals of Internal Medicine.

After controlling for other factors, a generic drug in the highest marketing competition group was expected to see a decrease of 32 percent in price over the study period, while a generic drug in the lowest market competition was expected to see a price increase of 47 percent over the same period.

These include patent expirations, the rise of competition from generics, a downward pressure on drug prices, increasing scrutiny from regulators and health technology assessment bodies, pressure to move research offshore, and the crisis in R&D productivity.

Similarly, prices of most other ADHD drugs would be higher — with an average increase of almost 4.6 % — with some, such as Dexedrine SR and its generic, increasing by as much as 8.69 % ($ 43.75 instead of $ 40.25) and 9.38 % ($ 38.42 instead of $ 35.14) respectively.

Researchers found that increasing the use of generic drugs and bringing Canadian drug prices in line with other countries where universal drug plans achieve better prices through bulk purchasing and negotiation, would add up to significant savings.

However, because the gains which have been made in reducing health care spending are largely attributable to price dynamics (such as reduced or no growth in physician reimbursement rates, and high use of cheaper generic drugs), the authors warn that any future economic recovery might reverse the progress that has been made in recent years.

In spite of all the efforts to raise awareness and address the problem of fake drugs, a major complication remains: Generic drugs, as well as branded drugs, are often produced overseas and many are sold online, which saves cost and can bring the price of medication down, making it affordable to many people.

We were originally attracted to TEVA because of its leading position in generic drugs, its free cash flow generation from its branded drug division, its recent dividend growth, and its cheap price to our estimation of its intrinsic value.

Generic drugs are very cheap in Thailand but unless you already have an idea of how much you should be paying, you will be charged double or triple the real price.

The Patent Act and the PM (NOC) Regulations seek to balance «effective patent enforcement» over new and innovative drugs with the «timely market entry» of lower priced generic versions once the patents have expired.

Currently represents a U.S. company in the Department of Justice's criminal investigation of price fixing of generic drugs

Relevant to the matter considered by the SJC, the Drug Price Competition and Patent Term Restoration Act, informally known as the «Hatch - Waxman Act» requires the «manufacturer of a generic drug [to] provide its users with a warning label that is identical to the label of the brand - name counterpart.&raDrug Price Competition and Patent Term Restoration Act, informally known as the «Hatch - Waxman Act» requires the «manufacturer of a generic drug [to] provide its users with a warning label that is identical to the label of the brand - name counterpart.&radrug [to] provide its users with a warning label that is identical to the label of the brand - name counterpart.»

U.S. Food and Drug Administration (FDA) Commissioner, Dr. Scott Gottlieb, has made generic drugs and drug pricing an agency priority by emphasizing the critical value of generic drugs to public heaDrug Administration (FDA) Commissioner, Dr. Scott Gottlieb, has made generic drugs and drug pricing an agency priority by emphasizing the critical value of generic drugs to public headrug pricing an agency priority by emphasizing the critical value of generic drugs to public health.

[10] Prior to 2006, the price at which manufacturers could apply to list generic drugs in the Formulary was capped by regulations under the Actsat effectively 63 % of the price of the brand - name drug.

Generally, generic drugs on the lowest priced tier, though this is not always the case — UnitedHealthcare makes a point to monitor the prices of high cost generics to make sure they're the best value.

In such patients, low priced generic risk pills that combine aspirin with a statin drug in order to reduce cholesterol and lower blood pressure can bring down the chances of suffering another stroke or even dying by two - thirds.

Professional Experience PCIVET (City, ST) Date — Date Purchasing Manager / Buyer • Managed all purchasing and procurement of branded and generic prescription drugs • Hired, trained, and directed support staff ensuring effective and efficient operations • Analyzed inventory movement, sales, and developed remedial strategies • Handled purchasing negotiations to secure quality products at competitive prices • Researched and evaluated product quality and sales potential prior to purchase